Form 4: CareDx Director William Hagstrom Exercises Options and Sells Shares Valued Over $386,000

CareDx, Inc. Director William A. Hagstrom executed a series of transactions on June 11, 2025, involving the exercise of stock options and the subsequent sale of common stock.

Summary

• On June 11, 2025, William A. Hagstrom, a Director of CareDx, Inc. (CDNA), engaged in a series of transactions involving the company's common stock.
• Mr. Hagstrom exercised options to acquire 15,000 shares of common stock at an exercise price of $14.74 per share, totaling $221,100.
• Additionally, he exercised options to acquire 4,391 shares of common stock at an exercise price of $7.96 per share, totaling $34,948.36.
• The options for 15,000 shares vested fully on June 20, 2019, and the options for 4,391 shares vested fully on June 16, 2024.
• Immediately following the option exercises, Mr. Hagstrom sold a total of 19,391 shares of common stock.
• These shares were sold at a weighted average price of $19.9019 per share, with individual transaction prices ranging from $19.69 to $20.20.
• The total value of the shares sold amounted to approximately $386,019.99.
• Following these transactions, Mr. Hagstrom's direct beneficial ownership in CareDx, Inc. stands at 53,979 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be viewed negatively, this appears to be a routine exercise-and-sell transaction for liquidity and monetization of vested equity, rather than a significant change in beneficial ownership or a signal of lack of confidence. The director still retains a substantial number of shares.

Positives

• The exercise of stock options indicates that the director is monetizing previously granted equity, which is a common practice for executive compensation.
• The sale price of the shares ($19.9019 weighted average) is significantly higher than the exercise prices ($14.74 and $7.96), indicating a profitable transaction for the director.

Negatives

• The sale of 19,391 shares by a director, even if it's an exercise-and-sell transaction, could be perceived by some investors as a lack of increased conviction in the company's near-term stock price appreciation, as the director did not retain the newly acquired shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are common occurrences in publicly traded companies. They often reflect an executive's personal financial planning, diversification strategies, or monetization of vested equity, rather than a direct statement about the company's future prospects. Such transactions are closely monitored by investors for insights into management's confidence and potential liquidity needs.

Stakeholder Impact

• Shareholders: May interpret the sale as a director taking profits, which could slightly influence sentiment, though it's a common liquidity event. The director's remaining beneficial ownership of 53,979 shares still aligns their interests with shareholders.
• Employees: No direct impact mentioned.

Key Dates

Keywords

CareDx, CDNA, SEC Form 4, Insider Trading, Stock Options, Director Transactions, Equity Sales, Beneficial Ownership, Executive Compensation